CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

ZUG, Switzerland and BOSTON, Sept. 28, 2022 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that... | September 28, 2022

Related Keywords

Boston ,Massachusetts ,United States ,California ,United Kingdom ,Switzerland ,London ,City Of ,San Francisco ,Susan Kim ,Rachel Eides ,Phuong Khanh ,Exchange Commission ,Vertex Pharmaceuticals ,Viacyte Inc ,Therapeutics Inc ,Drug Administration ,Globenewswire Inc ,Regenerative Medicine Advanced Therapy ,Mycosis Fungoides ,Chief Medical Officer ,Century Cures Act ,Breakthrough Therapy ,Orphan Drug ,Private Securities Litigation Reform Act ,Crispr Therapeutics Ag Stock Exchange ,News ,Information ,Press Release ,End ,022 ,Rispr ,Herapeutics ,Iopharmaceutical ,Company ,Ocused ,N ,Reating ,Ransformative ,Medicines ,Or ,Serious ,Oday ,Nnounced Crsp Ch0334081137 ,